Compare AMRC & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMRC | NUVB |
|---|---|---|
| Founded | 2000 | 2018 |
| Country | United States | United States |
| Employees | N/A | 291 |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 2010 | N/A |
| Metric | AMRC | NUVB |
|---|---|---|
| Price | $26.37 | $4.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | ★ $37.88 | $11.38 |
| AVG Volume (30 Days) | 418.0K | ★ 4.5M |
| Earning Date | 03-02-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.49 | N/A |
| Revenue | ★ $1,769,928,000.00 | N/A |
| Revenue This Year | $10.66 | $182.76 |
| Revenue Next Year | $8.93 | $91.83 |
| P/E Ratio | $54.77 | ★ N/A |
| Revenue Growth | ★ 28.76 | N/A |
| 52 Week Low | $8.49 | $1.57 |
| 52 Week High | $44.93 | $9.75 |
| Indicator | AMRC | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 41.58 | 34.35 |
| Support Level | $26.29 | $4.04 |
| Resistance Level | $31.12 | $5.73 |
| Average True Range (ATR) | 1.60 | 0.28 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 30.56 | 25.92 |
Ameresco Inc is an energy infrastructure solutions provider dedicated to helping customers reduce costs, enhance resilience, and decarbonize to net zero in the energy transition. Its comprehensive portfolio includes implementing smart energy efficiency solutions, upgrading aging infrastructure, and developing, constructing, and operating distributed energy resources. Its solutions range from upgrades to facility's energy infrastructure to the development, construction and operation of renewable energy plants combined with tailored financial solutions. Its segments include North America Regions, U.S. Federal, Renewable Fuels, Europe, and Others. The majority of the revenue is derived from North America Regions segment.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.